triolimus

a micellar preparation of paclitaxel, rapamycin, and tanespimycin

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

1.	Neoplasms (Cancer) 01/01/2017 - "Notably, pretreatment with high dose of Triolimus (High TRIO: PTX/17-AAG/RAP at 60/60/30 mg kg-1 ) before the fractionated radiation leads to tumor control for up to 24 weeks. " 10/01/2012 - "Triolimus was advanced into tumor xenograft models for assessment of efficacy, toxicity, and mechanisms of action. " 10/01/2012 - "In vivo, a three-infusion schedule of Triolimus inhibited A549 and MDA-MB-231 tumor growth far more potently than paclitaxel-containing micelles and effected tumor cures in MDA-MB-231 tumor-bearing animals. "
2.	Lung Neoplasms (Lung Cancer) 10/01/2012 - "In vitro cytotoxicity testing of Triolimus was conducted using two aggressive adenocarcinomas including the lung cancer cell line, A549, and breast cancer cell line, MDA-MB-231. "
3.	Breast Neoplasms (Breast Cancer) 10/01/2012 - "In vitro cytotoxicity testing of Triolimus was conducted using two aggressive adenocarcinomas including the lung cancer cell line, A549, and breast cancer cell line, MDA-MB-231. "
4.	Adenocarcinoma 10/01/2012 - "In vitro cytotoxicity testing of Triolimus was conducted using two aggressive adenocarcinomas including the lung cancer cell line, A549, and breast cancer cell line, MDA-MB-231. "